Arana Therapeutics

Arana Therapeutics, Ltd is an Australian biotechnology company focused on antibody development and traded on the ASX. Arana acquired Pepteck Limited and EvoGenix Limited to obtain their EvoGene™ technology for the development of antibodies and other proteins to enhance their properties as therapeutic and diagnostic products. EvoGenix also owns a proprietary binding scaffold with antibody-like properties called Evibodies™. Before being acquired by Cephalon for over 200 million Australian dollars in 2009, Arana advanced a novel anti-TNF antibody into Phase III clinical trials.